214 related articles for article (PubMed ID: 26486506)
1. BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer.
Kubo T; Kawano Y; Himuro N; Sugita S; Sato Y; Ishikawa K; Takada K; Murase K; Miyanishi K; Sato T; Takimoto R; Kobune M; Nobuoka T; Hirata K; Takayama T; Mori M; Hasegawa T; Kato J
Gastric Cancer; 2016 Jul; 19(3):827-38. PubMed ID: 26486506
[TBL] [Abstract][Full Text] [Related]
2. Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study.
Saito H; Fushida S; Miyashita T; Oyama K; Yamaguchi T; Tsukada T; Kinoshita J; Tajima H; Ninomiya I; Ohta T
BMC Cancer; 2017 Apr; 17(1):294. PubMed ID: 28449652
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
[TBL] [Abstract][Full Text] [Related]
4. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer.
Sasaki K; Onodera S; Otsuka K; Satomura H; Kurayama E; Kubo T; Takahashi M; Ito J; Nakajima M; Yamaguchi S; Miyachi K; Kato H
Med Oncol; 2017 Aug; 34(8):139. PubMed ID: 28707042
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
[TBL] [Abstract][Full Text] [Related]
7. Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer.
Mieno H; Yamashita K; Hosoda K; Moriya H; Higuchi K; Azuma M; Komori S; Yoshida T; Tanabe S; Koizumi W; Katada N; Watanabe M
Surg Today; 2017 Oct; 47(10):1249-1258. PubMed ID: 28365892
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.
Kim YW; Kim MJ; Ryu KW; Lim HS; Lee JH; Kong SY; Lee JS; Choi IJ; Kim CG; Lee JY; Cho SJ; Kook MC; Park YI; Kim SK; Park SR
Gastric Cancer; 2016 Apr; 19(2):586-596. PubMed ID: 25851942
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Okamoto K; Makino I; Nakamura K; Miyashita T; Tajima H; Takamura H; Ninomiya I; Ohta T
Eur J Surg Oncol; 2015 Oct; 41(10):1354-60. PubMed ID: 26028256
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer.
Oki E; Emi Y; Kusumoto T; Sakaguchi Y; Yamamoto M; Sadanaga N; Shimokawa M; Yamanaka T; Saeki H; Morita M; Takahashi I; Hirabayashi N; Sakai K; Orita H; Aishima S; Kakeji Y; Yamaguchi K; Yoshida K; Baba H; Maehara Y
Ann Surg Oncol; 2014 Jul; 21(7):2340-6. PubMed ID: 24604583
[TBL] [Abstract][Full Text] [Related]
13. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
Koizumi W; Kim YH; Fujii M; Kim HK; Imamura H; Lee KH; Hara T; Chung HC; Satoh T; Cho JY; Hosaka H; Tsuji A; Takagane A; Inokuchi M; Tanabe K; Okuno T; Ogura M; Yoshida K; Takeuchi M; Nakajima T;
J Cancer Res Clin Oncol; 2014 Feb; 140(2):319-28. PubMed ID: 24366758
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.
Migita K; Nashimoto A; Yabusaki H; Matsuki A; Aizawa M
Int J Clin Oncol; 2016 Feb; 21(1):102-9. PubMed ID: 26017926
[TBL] [Abstract][Full Text] [Related]
15. [Clinical development of chemotherapy for advanced gastric cancer].
Sato A; Matsukawa M
Nihon Shokakibyo Gakkai Zasshi; 2007 Feb; 104(2):186-93. PubMed ID: 17283412
[No Abstract] [Full Text] [Related]
16. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
17. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
Sato Y; Ohnuma H; Nobuoka T; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Shinya M; Katsuki S; Takahashi M; Maeda M; Okagawa Y; Naoki U; Kikuch S; Okamoto K; Miyamoto H; Shimada M; Takemasa I; Kato J; Takayama T
Gastric Cancer; 2017 May; 20(3):517-526. PubMed ID: 27553665
[TBL] [Abstract][Full Text] [Related]
18. Inflammation-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy.
Kunisaki C; Takahashi M; Ono HA; Oshima T; Takagawa R; Kimura J; Kosaka T; Makino H; Akiyama H; Endo I
Oncology; 2012; 83(4):183-91. PubMed ID: 22890015
[TBL] [Abstract][Full Text] [Related]
19. Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes.
Kitamura S; Tanahashi T; Aoyagi E; Nakagawa T; Okamoto K; Kimura T; Miyamoto H; Mitsui Y; Rokutan K; Muguruma N; Takayama T
Oncology; 2017; 93(2):127-135. PubMed ID: 28511180
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
Kosaka T; Akiyama H; Miyamoto H; Sato S; Tanaka Y; Sato K; Kunisaki C; Endo I
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1047-1055. PubMed ID: 30911769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
